San Francisco-based Achaogen announced Loeb as its new GC on Nov. 15. Loeb most recently served as GC to a San Francisco startup developing a biometric sensor. Before that, he was GC at Counsyl, a DNA screening company.
“[Achaogen] is a really exciting therapeutics company in a space that a lot of people don’t find quite as sexy, in some ways, as oncology,” Loeb said. “The antibacterial space has increasing need in the U.S. and worldwide, and I’m just really excited to join a company that’s looking into, frankly, an unmet need as far as developing new treatments.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
